EP 3316872 A4 20181226 - THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE
Title (en)
THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE
Title (de)
ZUBEREITUNG VON THERAPEUTISCHEN WIRKSTOFFEN ZUR FREISETZUNG IN EIN LUMEN DES DARMTRAKTES MIT EINER EINNEHMBAREN WIRKSTOFFFREISETZUNGSVORRICHTUNG
Title (fr)
PRÉPARATIONS D'AGENT THÉRAPEUTIQUE À ADMINISTRER DANS UNE LUMIÈRE DU TRACTUS INTESTINAL AU MOYEN D'UN DISPOSITIF D'ADMINISTRATION DE MÉDICAMENT AVALABLE
Publication
Application
Priority
- US 201562188408 P 20150702
- US 2016041013 W 20160705
Abstract (en)
[origin: WO2017004623A1] Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs/therapeutic agents within the GI tract. Many embodiments provide swallowable devices for delivering the agents. Particular embodiments provide a swallowable device for delivering drugs into the intestinal wall (IW). Embodiments also provide preparations including a plurality of glucose regulating compounds (GRC) that are configured to be contained within the capsule, advanced from the capsule into the IW and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW. Particular embodiments provide therapeutic preparations comprising insulin, GLP-1 and a third GRC where the third compound interacts with insulin or GLP-1 to produce an enhanced therapeutic effect in the patient.
IPC 8 full level
A61K 9/48 (2006.01); A61K 31/155 (2006.01); A61K 31/403 (2006.01); A61K 31/4985 (2006.01); A61K 31/70 (2006.01); A61K 31/7042 (2006.01); A61K 38/22 (2006.01); A61K 38/26 (2006.01); A61K 38/28 (2006.01); A61K 45/06 (2006.01)
CPC (source: EP)
A61K 9/0024 (2013.01); A61K 9/4825 (2013.01); A61K 31/155 (2013.01); A61K 31/403 (2013.01); A61K 31/4985 (2013.01); A61K 31/70 (2013.01); A61K 31/7042 (2013.01); A61K 38/22 (2013.01); A61K 38/2235 (2013.01); A61K 38/26 (2013.01); A61K 38/28 (2013.01); A61K 45/06 (2013.01); A61P 3/06 (2018.01); A61P 3/08 (2018.01); A61P 3/10 (2018.01); A61P 43/00 (2018.01)
C-Set (source: EP)
Citation (search report)
- [X] WO 2013003824 A1 20130103 - RANI THERAPEUTICS LLC [US], et al
- [XD] US 2013165372 A1 20130627 - IMRAN MIR [US]
- See also references of WO 2017004623A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2017004623 A1 20170105; AU 2016287843 A1 20180118; AU 2016287843 B2 20210617; CA 2993215 A1 20170105; CA 2993215 C 20231031; CN 108055826 A 20180518; EP 3316872 A1 20180509; EP 3316872 A4 20181226; JP 2018519313 A 20180719; JP 2020176152 A 20201029
DOCDB simple family (application)
US 2016041013 W 20160705; AU 2016287843 A 20160705; CA 2993215 A 20160705; CN 201680050621 A 20160705; EP 16818960 A 20160705; JP 2017567700 A 20160705; JP 2020133753 A 20200806